Key result
Incidental VTE was associated with similar mortality and recurrence rates compared to symptomatic VTE in both cancer and noncancer patients.
Why the study?
While recurrence risk is similar after incidental and symptomatic cancer-associated VTE, it was unknown whether this also applies to incidental VTE not associated with cancer.
Do early mortality and recurrence rates differ between incidental and symptomatic VTE in cancer and noncancer patients, and does anticoagulation therapy improve outcomes in incidental VTE?
Cohort (n=1,931)
Yes
Do early mortality and recurrence rates differ between incidental and symptomatic VTE in cancer and noncancer patients, and does anticoagulation therapy improve outcomes in incidental VTE?
Early mortality and recurrence rates are similar after incidental versus symptomatic VTE in both cancer and noncancer patients, and anticoagulation therapy for incidental VTE is associated with lower mortality and recurrence.
Answers are grounded in this paper and cite their sources.
Similar mortality/recurrence after incidental versus symptomatic VTE; supports comparable risk stratification but leaves anticoagulation benefit hypothesis-generating.
OBJECTIVE: In patients with cancer-associated venous thromboembolism (VTE), the risk of recurrence is similar after incidental and symptomatic events. It is unknown whether the same applies to incidental VTE not associated with cancer. METHODS AND RESULTS: = 1,931) VTE included in the SWIss Venous ThromboEmbolism Registry (SWIVTER). After incidental VTE, 114 (87%) patients received anticoagulation therapy for at least 3 months. The mortality rate was 9.2% after incidental and 8.4% after symptomatic VTE for hazard ratio (HR) 1.10 (95% confidence interval [CI] 0.49-2.50). After adjustment for competing risk of death, recurrence rate was 3.1 versus 2.8%, respectively, for sub-HR 1.07 (95% CI 0.39-2.93). These results were consistent among cancer (mortality: 15.9% vs. 12.6%; HR 1.32, 95% CI 0.67-2.59; recurrence: 4.8% vs. 4.7%; HR 1.02, 95% CI 0.30-3.42) and noncancer patients (mortality: 2.9% vs. 2.1%; HR 1.37, 95% CI 0.33-5.73; recurrence: 1.5% vs. 2.3%; HR 0.63, 95% CI 0.09-4.58). Patients with incidental VTE who received anticoagulation therapy for at least 3 months had lower mortality (4% vs. 41%) and recurrence rate (1% vs. 18%) compared with those who did not. CONCLUSION: In SWIVTER, more than half of incidental VTE events occurred in noncancer patients who often received anticoagulation therapy. Among noncancer patients, early mortality and recurrence rates were similar after incidental versus symptomatic VTE. Our findings suggest that anticoagulation therapy for incidental VTE may be beneficial regardless of the presence of cancer.
No takes yet. Share an insight, caveat, or question.
Spirk et al. (2020) conducted a cohort in Venous thromboembolism (n=1,931). Incidental VTE vs. Symptomatic VTE was evaluated on Mortality (HR 1.10, 95% CI 0.49-2.50). Incidental VTE was associated with similar mortality and recurrence rates compared to symptomatic VTE in both cancer and noncancer patients.
Synapse has enriched 10 related papers. Consider them for comparative context: